Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
USD0.69
-0.01 (-1.11%)
US NASDAQ Healthcare Medical - Healthcare Information Services
Address
325 Ellington Blvd. 20878
Gaithersburg, MD, US
Gaithersburg, MD, US
CEO
Vininder Singh
Website
bullfrogai.com
IPO
2023-02-13
CIK 1829247 ISIN US12021E1091
Also trades on
NASDAQ Capital Market · BFRG (USD)
NASDAQ Capital Market · BFRGW (USD)
Description
BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.69
-0.01 (-1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
946.3K
Beta
-2.81
Float Shares
10.22M
Free Float %
96.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.24% | -5.25% | -39.02% | +33.83% | -38.40% | -30.23% | -65.20% | -87.83% | -90.52% | -90.52% | -90.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.69
DCF (Unlevered)
211,251.34
+30,839,511.1%
DCF (Levered)
211,251.20
+30,839,490.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-2.89
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%—
-
EPS growth Medical - Healthcare Information Services: +43.1%+25.9% Q1'26: +42.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-5,587.1%
-
EBIT margin Medical - Healthcare Information Services: +8.8%-5,652.4%
-
ROIC Medical - Healthcare Information Services: +5.2%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+25.4% Q1'26: +33.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.52T
OE per share TTM
-483,612.58
Owner's Yield
-73,587,691.49%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,317,378.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 50.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
29.0K
Cash buys
—
Cash sales
1.00
Net activity
-29,002
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-25 | Hanson Jason David | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 1.43 | 21.5K | 15,000 | D | ↗ |
| 2025-09-25 | Enright William | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 1.43 | 21.5K | 15,000 | D | ↗ |
| 2025-09-25 | Elsey R Don | Director | A-Award | A | Stock Options (Right to Buy) | 15,000 | 1.43 | 21.5K | 15,000 | D | ↗ |
| 2025-08-22 | Singh Vininder | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 152,273 | 0.00 | — | 152,273 | D | ↗ |
| 2025-08-22 | Hanson Jason David | Director | A-Award | A | Common Stock | 5,710 | 0.00 | — | 5,710 | D | ↗ |
| 2025-08-22 | Enright William | Director | A-Award | A | Common Stock | 2,813 | 0.00 | — | 13,523 | D | ↗ |
| 2025-08-22 | Elsey R Don | Director | A-Award | A | Common Stock | 5,710 | 0.00 | — | 5,710 | D | ↗ |
| 2025-08-22 | Blacher Joshua | Officer | A-Award | A | Common Stock | 4,950 | 0.00 | — | 15,000 | D | ↗ |
| 2025-07-07 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 29,002 | 1.50 | 43.6K | 2,292,446 | D | ↗ |
| 2025-04-04 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 5,895 | 1.30 | 7.7K | 2,342,446 | D | ↗ |
| 2025-04-03 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 27,958 | 1.44 | 40.2K | 2,348,341 | D | ↗ |
| 2025-04-02 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 8,902 | 1.64 | 14.6K | 2,376,299 | D | ↗ |
| 2025-04-01 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 7,245 | 1.61 | 11.6K | 2,385,201 | D | ↗ |
| 2024-01-22 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 25,000 | 7.50 | 187.5K | 2,597,294 | — | ↗ |
| 2024-01-18 | Singh Vininder | Director / Officer / 10% Owner | A-Award | A | Stock options (Right to buy) | 79,000 | 4.28 | 338.1K | 79,000 | — | ↗ |
| 2024-01-18 | SAGLIO DANE R | Director / Officer | A-Award | A | Stock options (Right to buy) | 34,500 | 3.89 | 134.2K | 34,500 | — | ↗ |
| 2024-01-17 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 4,848 | 3.18 | 15.4K | 2,642,446 | — | ↗ |
| 2024-01-16 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 8,516 | 2.55 | 21.7K | 2,647,294 | — | ↗ |
| 2024-01-12 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,515 | 2.56 | 3.9K | 2,655,810 | — | ↗ |
| 2024-01-11 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 5,660 | 2.58 | 14.6K | 2,657,325 | — | ↗ |
| 2024-01-10 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 4,780 | 2.75 | 13.2K | 2,662,985 | — | ↗ |
| 2024-01-09 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 3,144 | 2.82 | 8.9K | 2,667,765 | — | ↗ |
| 2024-01-08 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 5,184 | 2.88 | 14.9K | 2,670,909 | — | ↗ |
| 2024-01-05 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,644 | 2.90 | 7.7K | 2,676,093 | — | ↗ |
| 2024-01-04 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 3,569 | 2.80 | 10.0K | 2,678,737 | — | ↗ |
| 2024-01-03 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 5,676 | 2.18 | 12.4K | 2,682,306 | — | ↗ |
| 2024-01-02 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 4,464 | 3.14 | 14.0K | 2,687,982 | — | ↗ |
| 2023-09-05 | Singh Vininder | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 50,000 | 2.95 | 147.5K | 2,692,446 | — | ↗ |
| 2023-06-14 | Enright William | Director | P-Purchase | A | Common Stock | 5,000 | 4.05 | 20.3K | 5,000 | — | ↗ |
| 2023-04-16 | Hanson Jason David | Director | A-Award | A | Stock options (Right to buy) | 40,000 | 6.82 | 272.8K | 40,000 | — | ↗ |
| 2023-04-16 | Enright William | Director | A-Award | A | Stock options (Right to buy) | 40,000 | 6.82 | 272.8K | 40,000 | — | ↗ |
| 2023-04-16 | Elsey R Don | Director | A-Award | A | Stock options (Right to buy) | 40,000 | 6.82 | 272.8K | 40,000 | — | ↗ |
| 2023-02-13 | Singh Vininder | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,742,446 | — | ↗ |
| 2023-02-13 | SAGLIO DANE R | Officer | — | D | Common Stock | 0 | 0.00 | — | 47,142 | — | ↗ |
| 2023-02-13 | Hanson Jason David | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-13 | Enright William | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-13 | Elsey R Don | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-16.5K
Shares Outstanding
10.61M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Vininder Singh Chief Executive Officer and Director | 400.0K | — | 288.6K | 129.0K | — | 347.00 | 818.0K | 51.06% | ↗ |
| 2 | 2025 | Josh Blacher Chief Financial Officer | 235.1K | — | 19.1K | — | — | — | 254.1K | 7.50% | ↗ |
| 3 | 2024 | Vininder Singh Chief Executive Officer and Director | 400.0K | — | — | 230.7K | — | — | 630.7K | 36.58% | ↗ |
| 4 | 2024 | Josh Blacher Chief Financial Officer | 10.6K | — | — | — | — | — | 10.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vininder Singh | Founder, Chairman & Chief Executive Officer | 400.3K | male |
| Joshua Blacher | Chief Financial Officer | 158.2K | male |
| David Recker FACP FACR | Chief Medical Officer | — | — |
| Antonio V. Montano | Chief Marketing Officer & Growth Strategy Leader | — | male |
| Praveen Kudithipudi | Chief Business Development Officer | — | — |
| J. T. Koffenberger | Chief Information Officer | — | male |
| Cetin Savkli | Chief AI Advisor & Member of Advisory Board | — | — |
ESG Rating
ESG Score History MEDICAL - HEALTHCARE INFORMATION SERVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BFRG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
